-- The Opto(TM) Cell Line Development 2.0 workflow, designed for the Beacon(R) 
optofluidic instrument, generates in just days the best production cell lines 
for complex antibody therapeutics with more than 99% monoclonality assurance 

Today, Berkeley Lights, a leader in cell selection, launched a new workflow for 
the Beacon instrument: the Opto Cell Line Development 2.0 (Opto CLD 2.0). While 
it takes traditional well plate workflows eight to twelve weeks to find clones 
producing traditional antibodies, Opto CLD 2.0 enables selection of top clones 
secreting complex antibody molecules with superior clonality assurance in less 
than one week.

Logo - https://mma.prnewswire.com/media/1078159/Berkeley_Lights_Logo.jpg 

The new Opto CLD 2.0 workflow enables measurements of antibody production 
across thousands of clones using Berkeley Lights' SpotLight(TM) assays.  It 
targets different regions of antibody molecules, extending the range of complex 
antibody molecules for which top clones can be selected. Screens can also be 
directed at clones with specific phenotypes, such as size, viability, or 
expression of cell-surface markers.

"The last decade has seen an explosion in more complex antibody molecules that 
have unique therapeutic functions, such as Fc-engineered mAbs, bispecifics and 
multispecifics," said John Proctor, Ph.D., Senior Vice President of Marketing 
at Berkeley Lights. "By developing new assays that target different regions of 
antibody molecules, Berkeley Lights Opto CLD 2.0 workflow empowers the 
selection of top clones secreting both traditional and non-traditional antibody 
molecules."

Opto CLD 2.0 builds on existing CLD capabilities on the Beacon instrument to 
screen and select clones with 1.5–3x higher titers than clones selected by 
traditional clone-picking technologies, which by comparison require a slow, 
laborious, and inefficient process. Cells can be visually tracked from the 
moment they are cloned into NanoPen(TM) chambers through multiple days of 
on-chip culture, assay measurements, and clone recovery. Top clones can be 
recovered with more than 99% monoclonality assurance and a superior data 
package that includes individual visual records of all clones.

The Opto CLD 2.0 workflow will be available for the Beacon instrument in June 
2020 and you can find more information here: 
https://www.berkeleylights.com/applications/cell-line-development.

About Berkeley Lights 
Here at Berkeley Lights, we think cells are awesome! Cells are capable of 
manufacturing cures for diseases, fibers for clothing, energy in the form of 
biofuels, and food proteins for nutrition. So the question is, if nature is 
capable of manufacturing the products we need in a scalable way, why aren't we 
doing more of this? Well, the answer is that with the solutions available 
today, it is hard. It takes a long time to find the right cell for a specific 
job, costs lots of money, and if you have picked a suboptimal cell line, has a 
very low process yield. Berkeley Lights has the complete solution to find the 
best cells by functionally screening and recovering individual cells for 
antibody discovery, cell line development, T cell analysis, and synthetic 
biology. Our proprietary technology, including the Beacon(R) and Lightning(TM) 
platforms, accelerate the rate you can discover and develop cell-based products 
in a fraction of the time and at a fraction of the cost of conventional, legacy 
research methods. Using our tools and solutions, scientists can find the best 
cells, the first time they look. For more information, visit 
www.berkeleylights.com.

Berkeley Lights' Beacon and Lightning platforms and Culture Station Instrument 
are: For Research Use Only. Not for use in diagnostic procedures. 

SOURCE: Berkeley Lights

CONTACT:  berkeleylights@bulleitgroup.com